BOULDER, Colo., Aug. 30, 2018 /PRNewswire/ -- Array
BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief
Executive Officer, Ron Squarer, will
speak at the Wells Fargo Securities 2018 Healthcare Conference in
Boston. The public is welcome to
participate in the conference through a webcast on the Array
BioPharma website.
|
Event:
|
Wells Fargo
Securities 2018 Healthcare Conference
|
|
Presenter:
|
Ron Squarer, Chief
Executive Officer, Array BioPharma
|
|
Date:
|
Thursday, September
6, 2018
|
|
Time:
|
3:05 p.m. Eastern
Time
|
|
Webcast:
|
https://cc.talkpoint.com/well001/090518a_as/?entity=47_0GHY12N
|
About Array BioPharma
Array BioPharma Inc. is a
fully-integrated, biopharmaceutical company focused on the
discovery, development and commercialization of transformative and
well-tolerated targeted small molecule drugs to treat patients
afflicted with cancer and other high-burden diseases. Array markets
in the United States
BRAFTOVITM (encorafenib) capsules in combination with
MEKTOVI® (binimetinib) tablets for the treatment of
patients with unresectable or metastatic melanoma with a
BRAFV600E or BRAFV600K
mutation. Array's lead clinical programs, encorafenib and
binimetinib, are being investigated in over 30 clinical trials
across a number of solid tumor indications, including a Phase 3
trial in BRAF-mutant colorectal cancer. Array's pipeline
includes several additional programs being advanced by Array or
current license-holders, including selumetinib (partnered with
AstraZeneca), larotrectinib (partnered with Loxo Oncology),
ipatasertib (partnered with Genentech), tucatinib (partnered with
Seattle Genetics) and ARRY-797 (being developed by Yarra
Therapeutics, a wholly-owned subsidiary of Array), all of which are
currently in registration trials. Ganovo® (danoprevir,
partnered with Roche) was recently approved in China for the treatment of viral hepatitis C.
For more information on Array, please visit www.arraybiopharma.com
or follow @arraybiopharma on Twitter and LinkedIn.
CONTACT:
Andrea N. Flynn, Ph.D.
Senior Director, Investor Relations & Corporate
Communications
(303) 381-6600
ir@arraybiopharma.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-present-at-the-wells-fargo-securities-2018-healthcare-conference-300703612.html
SOURCE Array BioPharma Inc.